

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: A61K 47/48, C08B 37/00	A1	(11) International Publication Number: WO 93/25239 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/US92/05091 (22) International Filing Date: 17 June 1992 (17.06.92) (71) Applicant: ADVANCED MAGNETICS INC. [US/US]; 61 Mooney Street, Cambridge, MA 02138 (US). (72) Inventors: JUNG, Chu ; 21 Coolidge Road, Arlington, MA 02174 (US). ENRIQUEZ, Philip ; 900 West Street, Shel- donville, MA 02070 (US). PALMACCI, Stephen ; 110 Granite Street, Walpole, MA 02081 (US). JOSEPHSON, Lee ; 14 Churchill Avenue, Arlington, MA 02174 (US). (74) Agents: SUNSTEIN, Bruce, D. et al.; Bromberg & Sun- stein, 10 West Street, Boston, MA 02111 (US).		(81) Designated States: CA, JP, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE). Published <i>With international search report.</i>
(54) Title: ARABINOGALACTAN DERIVATIVES AND USES THEREOF (57) Abstract There are provided a carrier for forming a complex with a therapeutic agent for delivery thereof to a cell receptor located on the surface of a target tissue comprising: arabinogalactan modified at a site by a functional residue to produce a derivative in a manner that preserves the useful affinity of the derivative for the cell receptor, and complexes thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

ARABINOGALACTAN DERIVATIVES AND USES THEREOF

5

Technical Field

This invention relates to the synthesis and methods of use of therapeutic agents targeted to cells, especially hepatocytes.

Background Art

10 The safety and efficacy of a therapeutic agent is a function of (i) its intrinsic biological activity and (ii) the biodistribution achieved after its administration. Many potentially useful therapeutic agents possess a biochemical activity ameliorating a particular pathological condition,
15 but the presence of the agent in normal, nonpathological tissue results in deleterious effects that prevent the use of the agent. Damage to a normally functioning kidney, bone marrow, liver tissue or other organ may limit the use of therapeutic agents with established antiviral activity, or
20 agents with established anti-cancer activity. There is a need for new compounds to target therapeutic agents to the specific cells that are the source of some pathological condition, and to reduce the concentration attained in unaffected, normal tissues. Targeting is the modification
25 of a therapeutic agent so that after injection or oral administration the uptake by a specific population of cells is increased relative to uptake of the unmodified agent. By targeting compounds with established and beneficial biological activity to specific tissues, compounds whose use
30 is currently limited by side effects might become safe and efficacious drugs. A therapeutic agent is a compound administered with the intent of changing in a beneficial manner some physiological function. Therapeutic agents include radioprotective agents, chemoprotective agents,
35 antiviral agents, antibodies, enzymes, and peptides.

One method of targeting therapeutic agents to specific cells involves attaching them to carrier molecules recognized by receptors performing receptor mediated endocytosis. Of particular interest is targeting via the

- 2 -

asialoglycoprotein receptor of hepatocytes. This receptor is present in high levels on normal hepatocytes but in lower levels or not at all on transformed hepatocytes (hepatoma cells). Diagnostic and therapeutic agents have been
5 attached to asialoglycoprotein carriers and neoglycoprotein carriers recognized by the asialoglycoprotein receptor and targeted to the cells, see Table II of Meijer and van der Sullies, Pharm. Res. (1989) 6:105-118 and Ranade, J. Clin. Pharmacol. (1989) 29:685-694. Molecules recognizing the
10 asialoglycoprotein receptor are most often either asialoglycoproteins or neoglycoproteins.

Asialoglycoproteins are formed by removing the sialic acid of glycoproteins and exposing galactose residues. Neoglycoproteins are formed by attaching multiple galactose
15 residues to non-glycoproteins such as human albumin.

When attaching diagnostic and therapeutic agents to a receptor-recognizing carrier molecule, targeting can be achieved only if the affinity of the carrier for the receptor is maintained. The differential reactivity of the
20 protein amine and carbohydrate hydroxyl groups of glycoprotein carriers, e.g. asialofetuin, is commonly used to achieve this goal. The highly reactive amine groups of protein lysine residues are selectively modified, while the hydroxyl groups of carbohydrate are left intact and continue
25 to recognize the receptor. Examples of this strategy are given in Van der Sluijs et al. (above) and in "Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands" (1991) Ed. G.Y. Wu and C.H. Wu, Marcel Dekker Inc. pp. 235-264. In contrast, a
30 polysaccharide such as arabinogalactan offers no polypeptide amino groups distal from the receptor binding site that can be modified for the purposes of retaining the asialoglycoprotein receptor binding activity. In spite of the obvious strategy for modification of glycoproteins with
35 retention of receptor binding activity, their use for targeted, parenteral pharmaceuticals is subject to several problems.

- 3 -

(i) Glycoproteins are prepared from animal cells and insuring noncontamination with human infective viral pathogens is a major issue.

(ii) Glycoproteins will not generally tolerate organic
5 solvents during conjugate synthesis, because such solvents frequently lead to a loss of biological activity and denaturation.

(iii) Glycoproteins can be toxic and/or antigenic.

(iv) Glycoproteins in their native form, e.g. fetuin,
10 do not afford galactose residues and must be desialylated to produce a carrier which interacts with the receptor.

Arabinogalactans are a class of polysaccharides obtained from the cell walls of many species of trees and other plants. A common, commercially available source of
15 arabinogalactan is the American Western larch (Larix occidentalis). Arabinogalactan from this source is used as a binder, emulsifier or stabilizer in foods. It consists of a largely 1-3 linked D-galactose backbone with 1-6 linked branch chains of L-arabinoses and D-galactoses at
20 practically every residue on the backbone. In larch arabinogalactans the ratio of galactose to arabinose is between 5 to 1 and 10 to 1, while arabinogalactans from plant sources in general range from about 1 to 4 to about 10 to 1 [Clarke, A.E., Anderson, R.L., Stone, B.A.;
25 Phytochemistry (1979) 18: 521-40]. Like many polysaccharides, arabinogalactans have different molecular weights with values of about 1-2 million to about 10,000 daltons [Blake, J.D., Clarke, M.L., Jansson, P.E.; Carbohydr Res (1983) 115: 265-272] having been reported. It has been
30 shown that L-arabinose and D-galactose interact with the asialoglycoprotein receptor while common monosaccharides like glucose or mannose do not [Lee, Haekyung, Kelm, Sorge, Teruo, Yoshino, Schauer, Roland Biol. Chem., Hoppe-Seyler (1988) 369, 705-714].

35 Some derivatives of arabinogalactan have been previously prepared. Graft copolymers have been used in paper manufacturing [SU1285094] and in soil treatments

- 4 -

[JP1051198]. Arabinogalactan sulfate has been used to form salts with drugs to influence drug absorption and prolong drug action [US4609640]. Acidic forms of arabinogalactan occur naturally having a composition which includes uranic acid [Clarke, A.E., Anderson, R.L., Stone, B.A., Phytochemistry (1979) 18, 521-40], and have also been prepared from arabinogalactan [JP60219202]. Derivatives of arabinogalactan with substituent alkyl, allyl cyano, halo or amino groups, and conjugates with organic acids and enzyme protein have been disclosed, wherein the carbohydrate is used as a carrier, adsorbent or resin [JP60219201]. In some cases arabinogalactan has been highly derivatized in a manner likely to destroy its interaction with the asialoglycoprotein receptor. For example, in some cases as many as 50% of the hydroxyl groups of arabinogalactan have been modified [JP60219201], but the affinity, or lack thereof, of arabinogalactan derivatives for the asialoglycoprotein receptor has not been studied.

Summary of Invention

The present invention provides for derivatives of arabinogalactan which can be used to target therapeutic agents to the cells possessing the asialoglycoprotein receptor.

The use of the polysaccharide arabinogalactan to target therapeutic agents to cells via the asialoglycoprotein receptor, a feature of the current invention, overcomes problems encountered when glycoproteins are used for this purpose.

(i) A polysaccharide like arabinogalactan originating from a plant source is unlikely to be contaminated with human viral pathogens.

(ii) Since arabinogalactan is a polysaccharide, it will tolerate exposure to organic solvents, which normally denature proteins during conjugate synthesis. Composed exclusively of sugars, the polysaccharide presents a narrow spectrum of reactive sites, an advantage compared to proteins where the variety of reactive sites can lead to

- 5 -

unwanted synthetic byproducts. This advantage is evident in the examples below.

(iii) Arabinogalactan has low toxicity and antigenicity.

5 (iv) Arabinogalactan in its natural form reacts with the asialoglycoprotein receptor. This helps reduce manufacturing cost because the deasialylation reaction normally used to expose the penultimate galactose of glycoproteins is avoided.

10 We have discovered that arabinogalactan can be modified in a number of ways to produce molecules which preserve the useful affinity for the asialoglycoprotein receptor. This is surprising since arabinogalactan does not afford protein or amino groups for selective modifications distal from the
15 receptor binding site. The ability to modify arabinogalactan while retaining its biological activity permits its use as a carrier for a wide variety of therapeutic agents with various targeting strategies.

In some instances targeting may be employed to deliver
20 a therapeutic agent to normal rather than pathological tissue. This strategy is employed when it is desirable to protect normal tissues from other generally toxic agents; in some cases agents of known but controlled toxicity are employed in therapy. The targeting of protective agents
25 used in conjunction with normally toxic radiation, as in radiation therapy, is an embodiment of the current invention and example of this type of targeting. The targeting of protective agents used with chemotherapeutic agents used in cancer treatment is another embodiment of the current
30 invention. The use of the term "therapeutic agent" in this description and the accompanying claims, includes agents which are protective from toxic chemicals or radiation.

The arabinogalactan derivatives of the invention must interact strongly with the asialoglycoprotein receptor, so
35 they can be used to target therapeutic agents to cells via that receptor. An assay to determine the strength of the interaction of arabinogalactan derivatives of the invention

- 6 -

with the receptor is presented.

In one embodiment the antiviral therapeutic agent adenosine arabinoside mono-5'-phosphate (ARA-AMP) is coupled to arabinogalactan. In addition, ARA-A or acyclovir, both
5 antiviral therapeutic agents, may also separately be coupled to arabino-galactans. In another embodiment the radioprotective agent S-2-(3 aminopropylamino) ethyl-thiophosphoric acid (known as WR2721) is attached to arabinogalactan. The invention provides methods and
10 compositions which enable the attachment of a variety of therapeutic agents to arabinogalactan and the delivery of those agents into the cytoplasm of cells via endocytotic activity of the asialoglycoprotein receptor.

Detailed Description of Specific Embodiments

15 The arabinogalactan used here in a preferred embodiment is highly purified and substantially free of endotoxins, and is derived from the Western Larch and has a single peak by size exclusion chromatography of about 20,000 daltons. Arabinogalactan can be used in its native, 20,000 dalton
20 form; alternatively polymers of arabinogalactan (molecular weight greater than the 20,000 dalton form), or degradative products (molecular weight below the 20,000 dalton form) can be used. Purified arabinogalactan has a single peak of 20,000 daltons by gel filtration, and a ratio of galactose
25 to arabinose of 5 to 1 as determined by the alditol acetate method. It binds the asialoglycoprotein receptor on hepatocytes [Josephson Groman et al. Mag. Res. Imag. (1990) 8: 637-646]. It has been shown that L-arabinose, and D-galactose interact with the asialoglycoprotein receptor
30 while, for example, common monosaccharides like glucose or mannose do not [Lee, Haekyung, Kelm, et al., Biol. Chem., Hoppe-Seyler (1988) 369: 705-714]. It has also been shown that an underivatized 4-hydroxy group on galactose and the clustering of suitable sugars, as is displayed by highly
35 branched polysaccharides like arabinogalactan, are important factors in binding the asialoglycoprotein receptor. Given these requirements, and based on the above composition and

- 7 -

structure, arabinogalactan is distinguishable from other polysaccharides including dextrans, starches, celluloses, inulins, 1-4 linked galactan and gum arabic. Though chemically distinguishable from arabinogalactan, gum arabic is another polysaccharide which like arabinogalactan interacts with the asialoglycoprotein receptor.

The present invention provides for conjugates of arabinogalactan with the therapeutic agents such as ARA-AMP or WR2721. The present invention also provides derivatives of arabinogalactan which interact with the asialoglycoprotein receptor. When an arabinogalactan derivative is recognized by the asialoglycoprotein receptor, a therapeutic agent can be targeted into the cells possessing that receptor, chiefly the hepatocytes.

Asialoglycoprotein receptors are dramatically reduced in primary hepatocellular cancers, and totally absent in secondary cancers to the liver, but are found in high concentration on normal hepatocytes [Josephson, Groman et al., Mag. Res. Imag. (1990) 8:637-646]. Hepatocytes are the predominant cell possessing this receptor, and endocytose a large proportion of injected radiolabelled asialoglycoproteins [Hubbard, Wilson et. al., J. Cell Biol. (1979) 83:47-64]. However, asialoglycoprotein receptors have been detected on Kupffer cells [Lee, Haekyung, et al. Biol. Chem. Hoppe-Seyler (1988) 369: 705-714], bone marrow cells [Samoloski and Daynes, Proc. Nat. Acad. Sci. (1985) 82:2508-2512] and rat testis [Abullah and Kierszenbaum, J. Cell Biol. (1989) 108: 367-375]. Useful amounts of a therapeutic agent may be targeted to any asialoglycoprotein receptor positive cell. Similarly any receptor positive cell, including stem cells, may be protected with a receptor targeted radioprotective agent based on arabinogalactan.

ARA-AMP is an antiviral therapeutic agent that has been evaluated in the treatment of hepatitis B, though its use is associated with serious neurological side effects [Lok, A.S., Wilson, L.A. et al., J. Antimicrob. Chemother. (1984) 14: 93-9; Hoffnagel, J.H. et al., J. Hepatol. (1986)

- 8 -

3: S73-80]. ARA-AMP conjugated to arabinogalactan, and targeted to asialoglycoprotein receptor possessing cells where viral replication is ongoing (hepatocytes), is expected to reduce unwanted side effects by reducing the concentration of the drug in the central nervous system and increasing the concentration of the drug in the organ of viral replication. ARA-AMP has been coupled to a glycoprotein recognized by the asialoglycoprotein receptor [US 4794170]. Other antiviral therapeutic agents which may be used for this purpose include acyclovir and Ara-A.

A second type of anti-viral agent that can be targeted with the teachings of the invention are antibodies. In this context antibodies may include polyclonal antibodies, monoclonal antibodies or antibody fragments. The natural occurrence of antibodies in serum reflect past exposure to a virus but may have little or no protective activity because viral replication occurs within the cytoplasm of cells [I.M. Roitt, "Essential Immunology," Blackwell Scientific, London (1991), p. 28]. In particular hepatitis B virus replication occurs within the hepatocytes of the liver and antibodies to viral antigens cannot directly bind the virus during this replication. If an antibody to a hepatitis B viral protein is conjugated to arabinogalactan, it will be targeted via the asialoglycoprotein receptor to the cytoplasm of hepatocytes. Within the cytoplasm the antiviral antibody will bind replicating hepatitis B virus and become an effective therapeutic agent.

Some of the arabinogalactan derivatives described have no known pharmacological activity, other than their ability to bind the receptor, but provide a substrate for attaching therapeutic agents, e.g., attachment to the amino, carboxyl, sulfhydryl, phosphoryl or other functional groups of the derivative. The resulting conjugate will target the therapeutic agent to cells possessing the asialoglycoprotein receptor, principally the hepatocytes of the liver. The carboxyl groups afforded by the succinyl-arabinogalactan, glutaryl-arabinogalactan and DTPA-arabinogalactan conjugates

- 9 -

(Examples 10-12) can be used to attach molecules through the use of carboniimides or other agents. The amino groups afforded by the arabinogalactan hydrazide (Example 3) or poly-L-lysine arabinogalactan (Examples 6, 8) can also be used to attach therapeutic agents by a variety of reactions. The strong positive charge of poly-L-lysine can cause some agents such as negatively charged nucleic acids to adhere by ionic exchange forces [Wu, G.Y. and Wu, C.H., J. Biol Chem. (1987) 262: 4429-2232]. A preferred embodiment of this invention is a composition comprising arabinogalactan and poly-L-lysine, wherein the intended use is as a carrier for genes or antisense oligonucleotides used in parenteral administration [Degols, G., Leonetti, J.P., Gagnor, C., Lemaitre, M., Lebleu, B., Nucleic Acids Res (1989) 17: 9341-50]. In addition to poly-L-Lysine, other polymeric molecules, such as dextrin, dextran, or albumin may be coupled to arabinogalactan.

In another embodiment, galactose oxidase treatment of arabinogalactan can be used to create aldehyde groups. The aldehyde groups can be reacted with diamino compounds (e.g. ethylenediamine), to form a Schiff base, followed by reduction with sodium borohydride. The resulting amino derivative of arabinogalactan can then be used for the attachment of therapeutic agents.

Similarly WR2721 has been the subject of recent clinical studies to ascertain whether it can be used to protect the normal cells of cancer patients during radiotherapy [Kligerman, M.M., Liu, T., Liu, Y., He, S., Zhang, Z., 7th International Conference on Chemical Modifiers of Cancer Treatment (1991), Clearwater, FA 338-340] or chemotherapy [Schein, P.S, International Conference on Chemical Modifiers of Cancer Treatment (1991), Clearwater, FA 341-342]. The utility of WR2721 as a chemoprotectant has been objected to based on the lack of evidence that it selectively protects normal cells; i.e. it may protect normal and cancer cells from radiation [The Pink Sheet, Feb 3, 1992, 54, #5]. The attachment of WR2721 to

- 10 -

arabinogalactan will overcome this shortcoming, directing the agent to cells possessing the asialoglycoprotein receptors. The radioprotective activity of WR2721 will be targeted to normal cells since the asialoglycoprotein
5 receptor is found chiefly on non-cancerous hepatocytes, see above.

Free radical scavengers other than WR2721 can be attached to arabinogalactan, and targeted to receptor bearing cells. These scavengers include melanins [Hill,
10 H.Z., Huselton, C., Pilas, B., Hill, G.J.; Pigment Cell Res (1987) 1: 81-6], Trolox [Wu, T.W., Hashimoto, N., Au, J.X., Wu, J., Mickle, D.A., Carey, D.; Hepatology (1991) 13: 575-80], cysteamine derivatives [Schor, N.F., Siuda, J.F., Lomis, T.J., Cheng, B.; Biochem J (1990) 267: 291-6],
15 cationic aminothiols generally, glutathiols, and vitamin E derivatives.

After synthesis, the interaction of the arabinogalactan derivative with the asialoglycoprotein receptor can be determined in vivo. The ability of a derivative to interact
20 with the asialoglycoprotein receptor is assessed by its ability to block the clearance of a substance recognized to interact with the asialoglycoprotein receptor based on earlier work. An arabinogalactan coated superparamagnetic iron oxide colloid interacts with this receptor and a
25 quantitative assay for its clearance has been described below. In the absence of a blocking agent, the arabinogalactan coated superparamagnetic iron oxide is rapidly cleared via the asialoglycoprotein receptor with a blood half-life of 2.8 minutes. The interaction of free
30 arabinogalactan with the asialoglycoprotein receptor effects an increase in blood half-life of this substance, providing a basis for evaluating the blocking ability of arabinogalactan derivatives.

To obtain the blood half-life a Sprague-Dawley rat
35 (200-300 grams) is anesthetized (100 mg/kg of Inactin) and injected with a defined dose of a blocking agent, followed by an arabinogalactan coated superparamagnetic iron oxide at

- 11 -

40 umoles Fe/kg. Blood is withdrawn and $1/T_1$, the spin-spin relaxation rate, determined. The enhancement in $1/T_1$ is directly proportional to the concentration of superparamagnetic iron oxide, and from changes in $1/T_1$ the blood half-life is determined as described [Josephson et al. Mag Res. Imag. (1990) 8: 637-646].

Table 1 indicates that arabinogalactan can tolerate a substantial degree of modification produced by many different types of reactions, without losing its activity as a blocking agent (receptor binding activity). With antibodies and enzymes, covalent modification especially high levels of covalent modification, generally decreases or destroys biological function. Thus it is surprising that arabinogalactan tolerates random modification with excellent retention of its receptor-recognizing biological activity. In fact two derivatives tested, the phosphoryl arabinogalactan and succinyl-arabinogalactan, were more potent as blocking agents than the parent arabinogalactan. The basis for this highly surprising improved reactivity is unknown. In contrast, lactose, a disaccharide-containing galactose, is substantially less active a blocker than arabinogalactan.

The ability of a derivatization procedure to damage the binding affinity of arabinogalactan for the asialoglycoprotein receptor is shown by example 18. The acetate derivative has greater than 5 milli-equivalents of acetate per gram of arabinogalactan acetate and exhibited substantially reduced blocking activity.

If an arabinogalactan conjugate is inactive in the blocking assay, i.e., does not prolong blood half-life, conditions used in conjugate synthesis can be adjusted to achieve a lower degree of modification. Alternatively, the modification strategy employed may be dropped altogether and a different procedure employed.

- 12 -

TABLE 1

Interactions of arabinogalactan derivatives
with the asialoglycoprotein receptor

5

Agent	Dose Blocking Agent (mg/kg)	Half-life (min)
None	none	2.8
lactose	300	8.0
arabinogalactan	150	33.2
10 phosphoryl- arabinogalactan (Example 9)	150	51.0
15 succinyl arabinogalactan (Example 11)	150	213
arabinogalactan-AMP (Example 4)	150	>100
arabinogalactan- WR2721 (Example 15)	150	86
20 arabinogalactan acetate (Example 18)	150	7.3
25 arabinogalactan propionate (Example 19)	150	40.8

The examples below demonstrate that arabinogalactan can be modified by the addition of phosphoryl, sulfhydryl, amino, carboxyl, halo, or acylimidazol groups, with receptor
30 binding activity being unaffected. The initial modification is performed on the hydroxyl groups on the arabinogalactan.

- 13 -

The derivatives can be used to prepare conjugates with therapeutic agents, as for example arabinogalactan-WR2721 or arabinogalactan-AMP (Table 1). In some cases we describe the preparation of amino or carboxy arabinogalactan derivatives with no known therapeutic activity. These derivatives can be used to attach a wide range of drugs or ligands to the amino or carboxy groups of derivatized arabinogalactan, with generally known crosslinking and conjugation chemistries. These derivatives can also be used to attach macromolecules like genes, proteins, antibodies and enzymes to arabinogalactan. A recent compendium of applicable reactions is S.W. Wong, "Chemistry of Protein Conjugation and Cross-linking," CRC Press Boca Raton, 1991). Reagents used to couple proteins to solid phase amino or carboxyl groups can also be used after minor modifications (see I. Chibata, "Immobilized Enzymes," Halstead Press, New York 1978). Some examples of therapeutic agents that can be conjugated to arabinogalactan to provide useful pharmaceutical agents are listed in Table 2.

20

- 14 -

TABLE 2

Therapeutic agents that have been or might be attached
to arabinogalactan or arabinogalactan derivatives

5

Agent	Class	Reference
Ara-AMP	antiviral activity	Example 5
WR2721	chemo- and radioprotective activity	Example 14
Pepstatin	anti-inflammatory activity	Example 17
10 DNA	gene therapy	Examples 6, 8
Antisense nucleic acid	antiviral activity	Examples 6, 8
15 Antibody to hepatitis	antiviral activity	
Steroid anti-inflammatory activity		
20 Superoxide dismutase anti-inflammatory activity		

Examples

25

Example 1: Bromination of arabinogalactan.

The arabinogalactan (AG) used is from the Western Larch and chromatographs produce a single peak of about 20,000 daltons by size exclusion chromatography.

30

Ten grams of arabinogalactan are dissolved in 35 ml of

- 15 -

a 7.1% (w/v) solution of $\text{Zn}(\text{BF}_4)_2$. Fifty ml of epibromohydrin is added and the solution stirred for 90 minutes at 100°C. The bromo-arabinogalactan is precipitated in 150 ml cold (4°C) acetone, redissolved in water, and
5 precipitated in 150 ml cold ethanol. Analysis of the product for bromine showed 0.7 milliequivalents bromide per gram product.

Example 2: Treatment of arabinogalactan with sodium borohydride.

10 Ten grams sodium borohydride is added to 3,500 grams of a 28.6% (w/w) solution of arabinogalactan. The mixture is stirred overnight, and then dialyzed for six days against 35 liters of water (changing the water daily) using 3,500 dalton cut-off dialysis tubing to remove unreacted NaBH_4 .

15 The 3-methyl-2-benzothiazolone hydrazone test for aldehyde is used to compare the aldehyde content of the arabinogalactan starting material to sodium borohydride reduced arabinogalactan. Arabinogalactan showed the blue dye formation characteristic of aldehyde, reduced
20 arabinogalactan produced no dye, indicating essentially complete reduction.

Example 3: Hydrazino-arabinogalactan.

Ten grams of reduced arabinogalactan (Example 2) is dissolved in 35 ml of a 7.1% (w/v) aqueous solution of
25 $\text{Zn}(\text{BF}_4)_2$. Fifty ml of epibromohydrin is added and the solution stirred for 90 minutes at 100°C. The brominated arabinogalactan is precipitated in 150 ml cold (4°C) acetone, redissolved in water, and precipitated in 150 ml cold ethanol. Five grams of this brominated arabinogalactan
30 product is dissolved in 15 ml of 0.3 M aqueous borate, pH 8. Ten grams hydrazine is added and the mixture is stirred for 24 hours at room temperature. The hydrazido-arabinogalactan is precipitated in 150 ml cold (4°C) acetone, redissolved in water and precipitated in 150 ml cold ethanol. The product
35 hydrazide content is analyzed by acid-base titration and showed 0.25 milliequivalents hydrazide per gram of product.

- 16 -

Example 4: Arabinogalactan conjugated to adenosine 5' monophosphate (AMP)

One gram (2.9 mmoles) of adenosine 5'-monophosphate (AMP) is dissolved in 20 ml water with the addition of sodium bicarbonate powder. Arabinogalactan-hydrazide (0.6 g, example 2) is added and the pH adjusted to 7.5 with sodium hydroxide. One gram (5.2 mmoles) of 1-ethyl-3,4-dimethylaminopropyl carbodiimide is added and the reaction maintained at room temperature for 64 hours. The product is purified by ultrafiltration using an Amicon YM3 ultrafilter, further purified by precipitation from ethanol. A yield of 323 mg of product was obtained. The product was analyzed by cation exchange chromatography (Rainin Synchropak, strong cation exchange So 300 A, 25 x 0.5 cm column) using a buffer of 0.1 mM, pH 7.0 phosphate buffer at flow rate 0.5 ml/min). A single broad peak at 5.7 minutes with no evidence for underivatized AMP (retention time 6.3 minutes) was observed. The number of AMP molecules per gram of AG-AMP product, based on the comparison of HPLC area under the curve monitoring at 260 nm is 0.24, indicating approximately a 95% conversion of available hydrazide groups. The UV/VIS spectrum of the AG-AMP product is virtually identical to underivatized AMP. The analysis of product by size exclusion (Amicon Cellufine GC200M) chromatography shows a molecular weight approximately equivalent to underivatized arabinogalactan, about 20,000 daltons.

The activity of AG-AMP was evaluated in the animal model as described above. 150 mg/kg of this substance was an effective blocker of the superparamagnetic iron-oxide colloid, extending the half-life of the colloid to greater than 100 minutes (Table 1).

Example 5: Arabinogalactan conjugated to adenine arabinoside 5' monophosphate (ARA-AMP).

One gram (2.9 mmoles) of adenine arabinoside 5'-monophosphate (ARA-AMP) is dissolved in 20 ml water with the addition of sodium bicarbonate powder. 0.6 grams of arabinogalactan-hydrazide (Example 2 above) is then added

- 17 -

and the pH adjusted to 7.5 with the addition of sodium hydroxide. One gram (5.2 mg) of 1-ethyl-3,4-dimethylaminopropyl carbodiimide is added and the reaction maintained at room temperature for 64 hours. The product is
5 purified by ultrafiltration using an Amicon YM3 ultrafilter, and then further purified by precipitation from ethanol and dried, yielding 280 mg of product. As with AG-AMP (Example 3), the strong cation exchange chromatography showed a single broad peak centered at 5.7 minutes and no measurable
10 residual unreacted ARA-AMP. The UV/VIS spectrum of AG-ARA-AMP was virtually identical to an ARA-AMP standard. Based on the area under the curve at an optical density of 260 nanometers and in comparison with an AMP standard, which is assumed to have the same extinction coefficient as ARA-AMP,
15 the product has 0.124 milli-equivalents of ARA-AMP per gram.

Example 6: Poly(L)lysyl-arabinogalactan (prepared by reductive amination).

Poly(L)lysine hydrochloride (1,000-4,000 daltons, 0.5 grams) is dissolved in 2 ml borate buffer (0.2M) and the pH
20 adjusted to 9.0 with sodium hydroxide. 100 mg arabinogalactan and 50 mg sodium cyanoborohydride is added. and the reaction heated for 24 hours at 50°C. The product mixture is purified using an Amicon YM3 ultrafilter. The retentate containing the polylysine-arabinogalactan
25 conjugate showed a positive ninhydrin test for amine and positive anthrone test for polysaccharide. The yield was 30 mg. Size exclusion high performance liquid chromatography (Amicon Cellufine GC200M) showed a product having a molecular weight approximately equal to the sum of molecular
30 weights of arabinogalactan and poly(L)lysine or about 25,000 daltons.

Example 7: Acylimidazole-arabinogalactan.

Three grams of anhydrous arabinogalactan is suspended in 5 ml of anhydrous peroxide free dioxane. While stirring,
35 1.62 gm (10mmole) of N,N'-carbonyl diimidazole, dissolved in 10 ml of dioxane, is added in a single portion. After stirring for 20 minutes the acylimidazol-arabinogalactan is

- 18 -

collected by filtration (medium frit). The product is washed with 25 ml of dioxane and refiltered. A second dioxane titration is performed. The product is next titrated with 25 ml of apf-diethyl ether and then vacuum dried. Yield is 2.9 gm.

Example 8: Poly(L)lysine-arabinogalactan (prepared from acylimidazole-arabinogalactan).

One gram of acylimidazole-arabinogalactan (Example 7) and 0.2 grams poly(L)lysine (1,000-4,000 daltons) is dissolved in 5 ml of 0.2M borate buffer and the pH adjusted to 8.6 with sodium hydroxide. The reaction is allowed to proceed for 24 hours at 5°C. The product is isolated first by precipitation in ethanol, and then purified using an Amicon YM10 ultrafilter. The retentate shows a positive test for amine and carbohydrate using the ninhydrin and anthrone tests, respectively, while the final filtrate is negative for amine. The yield is 310 mg.

The product poly(L)lysyl-arabinogalactan is analyzed by cation exchange chromatography HPLC (Rainin Synchropak strong cation exchange resin, So 300A, 25 X 0.5 cm), using pH 5.5, 25 mM phosphate buffer at a 1 ml/min flow rate. The product, arabinogalactan-polylysine, elutes with a retention time of 3.9 minutes whereas unconjugated polylysine elutes with a retention time of 9.3 minutes. Poly(L)lysine bound to arabinogalactan is verified by its UV spectrum.

Example 9: Phosphoryl-arabinogalactan.

Two grams of arabinogalactan are dissolved in 20 ml formamide and 4 ml triethylamine. Ten grams polyphosphoric acid are added and the reaction stirred for 16 hours. The product is brought to pH 9 with 45% NaOH and ultrafiltered in a 50 ml stirred cell with a 3,000 molecular weight cutoff membrane (Amicon), bringing the volume from 50 ml to 10 ml twice. The ultrafiltered product is precipitated into 500 ml cold acetone (4°C), redissolved, and precipitated in 500 ml cold ethanol. The product showed 0.21 milli-equivalents of phosphate per gram of product both by acid base titration

- 19 -

and by colorimetric quantitation of inorganic phosphate (inorganic phosphorus kit, Sigma Chemical, St.Louis, MO) following trifluoroacetic acid hydrolysis (2M acid for 1 hour at 120°C).

5 The activity of phosphorylated arabinogalactan was evaluated in the animal model as described above. 150 mg/kg of this substance was an effective blocker of the superparamagnetic iron-oxide colloid, extending the half-life of the colloid to greater than 51 minutes (Table 1).

10 Example 10: Treatment of arabinogalactan with galactose oxidase (GO).

Ten grams of arabinogalactan is dissolved to a total volume of about 50 ml in 0.1 M potassium phosphate buffer, pH = 6.0. To the resultant solution is added 225 units of
15 galactose oxidase dissolved in about 2 ml of the same buffer. The oxidation is allowed to proceed for 24 hours at room temperature. The H₂O₂ content is found to be about 3 mg/ml, as measured by peroxide test strips. A second addition of 225 units of GO is made to the reaction mixture.
20 After another 24 hour reaction period the peroxide content is found to be unchanged from the result of the first GO treatment at about 3 mg/ml. Twenty milligrams of catalase (dry solid) is added to decompose the peroxide. After standing at room temperature overnight the contents of the
25 flask are found to be free of peroxide.

Product Purification. Ten grams of mixed bed resin, MB-1 is added to the flask. After stirring for 30 minutes the solution is decanted into and passed through a short column containing an additional 5 grams of MB-1 resin. The
30 pH neutral solution is found to be free of any protein amines by reaction with ninhydrin. The product is isolated by precipitation from 5°C cooled absolute ethanol. The precipitate is collected by filtration. The aldehyde content of this product is found to be between 3 and 5 times
35 greater than the aldehyde content of native arabinogalactan. Yield is 10 grams.

Determination of the Number of Aldehyde Groups: The 3-

- 20 -

methy1-2-benzothiazolone hydrazone test for aldehyde was used to compare arabinogalactan starting material to poly-aldehydic arabinogalactan. Based on absorbance measured at 670 nm, this poly-aldehydic arabinogalactan has 0.34 milli-

5 equivalents aldehyde per gram of arabinogalactan.

Example 11: Succinyl-arabinogalactan.

Purified arabinogalactan (16.0 g, 0.70 mmol) and succinyl anhydride (10.0 g, 100 mmol) were dissolved in DMSO (200 ml) at 60°C. After 1.0 hour, the clear, light yellow
10 solution was cooled to ambient temperature and allowed to stir for an additional 48 h. The DMSO solution was added to H₂O (200 ml), filtered on an Amicon YM3 ultrafiltration membrane and washed with H₂O (3 times with 250 ml). The solution remaining on the membrane was frozen and
15 lyophilized. Yield of white powder: 20.6 g. IR (KBr): 1732 cm⁻¹ (C=O). Titration of an aqueous solution of the conjugate with 0.01 N NaOH indicated the presence of 1.96 milli-equivalents succinate per gram of succinyl-arabinogalactan.

20 The activity of succinyl-arabinogalactan is evaluated in the animal model as described above. 150 mg/kg of this substance was an effective blocker of the superparamagnetic iron-oxide colloid, extending the half-life of the colloid to 213 minutes (Table 1).

25 Example 12: DTPA-arabinogalactan.

Purified arabinogalactan (20.0 g, 0.87 mmol) and the dianhydride of diethylenetriaminepentaacetic acid (DTPA) (2.15 g, 6.02 mmol) were dissolved in dimethylsulfoxide (DMSO, 200 ml) at 60°C. After 0.5 hour, the clear solution
30 was added to H₂O (ca. 500 ml) at 15°C. The solution was filtered on an Amicon YM3 and YM1 ultrafiltration membranes (5,000 and 1,000 dalton cutoff, respectively) and washed with H₂O (2 X 400 ml). The solution (70 ml) remaining on the membrane was frozen and lyophilized. Yield of white
35 powder was 18.8 g. The IR showed a band at 1734 cm⁻¹ (C=O). Titration of an aqueous solution of the conjugate with 0.010 N NaOH indicated the presence of 0.117 milliequivalents DTPA

- 21 -

per gram DTPA-arabinogalactan.

Example 13: Glutaryl-arabinogalactan.

Purified arabinogalactan (20.0 g, 0.87 mmol) and glutaric anhydride (5.00 grams, 44 mmol) were dissolved in DMSO (200 ml) at 60°C. The reaction mixture was cooled to ambient temperature and allowed to react for 16 hours. The DMSO solution was added to H₂O (200 ml), filtered on an Amicon YM3 ultrafiltration membrane and washed with H₂O (2 times 300 ml). The solution remaining on the membrane was frozen and lyophilized. Yield of white powder: 18.5 g (lot number 2127-179). IR (KBr): 1726 cm⁻¹ (C=O).

Example 14: S-2-(3 aminopropylamino) ethyl-thiophosphate-dextran-arabinogalactan from thiophosphorylated dextran.

Polythiophosphorylation of dextran. Ten grams of dextran is suspended in 60 ml of anhydrous pyridine. The suspension is cooled in an ice water bath. To the cooled suspension is added dropwise with stirring 10 ml (98.4 mmoles) of thiophosphoryl chloride. Once the addition is complete the reaction mixture is allowed to warm to room temperature with constant stirring. The reaction flask is then immersed in an oil bath and heated for 16 hours at 40°C.

The slightly yellow colored reaction mixture is cooled in an ice bath. Once cooled, water is added slowly dropwise while the reaction suspension is vigorously stirred. After about 10 ml of water has been added to the reaction mixture a solution of 1 N NaOH is added until a pH of 9.5 is reached. The solution is then evaporated at room temperature to an oil. The residue is mixed with 20 ml of water, which results in a clear homogeneous solution. This solution is added dropwise to 200 ml of 0°C ethanol which is vigorously stirred. The resulting white precipitate is collected on a coarse fritted funnel and dried under vacuum.

Titration with 0.5 M hydrochloric acid indicates that 1 mmole of thiophosphate is incorporated per gram of polysaccharide.

Synthesis of 2-(3-aminopropylamino) ethyl bromide.

- 22 -

dihydrobromide. Twenty three and six-tenths grams (200 mmole) of ice cold 2-(w-aminopropylamino) ethanol is added portionwise to 200 ml of ice cold 48-52% hydrobromic acid. After stirring for 1 hour the reaction mixture is heated to
5 reflux for 16-20 hours. The reaction mixture is vacuum dried to a reddish colored oil. The oil is titrated with 300 ml of acetone and left under refrigeration for 4 hours. The mother liquor of acetone is decanted away from the gummy residue. The residue is dissolved with 75 ml of water and
10 the resulting solution is added to 600 ml of cold acetone. The crystalline precipitate is collected and then dissolved in boiling methanol. The resulting methanol solution is added to a 50% mixture of ethyl ether and acetone (400 ml). After cooling the mixture overnight the pure white crystals
15 are collected and vacuum dried. The melting point of the product is 205-206°C, as reported [Piper, J.R., et.al. (1969), J. Med. Chem 12: 236-243].

Reaction of polythiophosphorylated dextran with 2-(w-aminopropylamino) ethyl bromide to form S-2-(3
20 aminopropylamino) ethyl-thiophosphate-dextran. Five mmoles of polythiophosphorylated dextran, sodium salt, is dissolved in 10 ml of water. To the above solution is added 5.5 mmoles of 2-(3-aminopropylamino) ethyl bromide dihydrobromide dissolved in 10 mls of water. The clear
25 solution is stirred for four hours at room temperature. The resulting turbid solution is added dropwise to rapidly stirred 0°C ethanol. The resulting precipitate is collected by filtration. The product is washed with twice with 25 ml portions of warm (40-50°C) ethanol and vacuum dried.
30 The extent of thioalkylation is determined by a colorimetric analysis with ninhydrin.

Reaction of S-2-(3 aminopropylamino) ethyl-thiophosphate-dextran with Arabinogalactan-acylimidazole
S-2-(3 aminopropylamino) ethyl-thiophosphate-dextran is
35 reacted with arabinogalactan-acylimidazole (Example 7) at 4°C for 16 hours. The product is isolated and purified by ultrafiltration using a YM10 filtration membrane.

- 23 -

Example 15: Arabinogalactan-WR2721 from brominated arabinogalactan.

Reduced arabinogalactan is brominated as described in Example 3. 2 grams of this brominated arabinogalactan is added to 1 gram of WR2721 in 10 ml of 0.2M borate and the pH adjusted to 8.0. The mixture is stirred for 16 hours at room temperature. Arabinogalactan-WR2721 is purified by Amicon YM3 ultrafiltration, then precipitated in acetone and redissolved in water. Finally it is precipitated in ethanol and dried. The final product is dissolved in 0.1 N HCl and titrated with 0.1 N NaOH. Using WR2721 as a reference for the titration, the arabinogalactan-WR2721 final product was shown to have 0.66 milli-equivalents of WR2721 per gram of product. The product analyzed by size exclusion chromatography (Amicon Cellufine GC200M) shows the major component has a molecular weight of about 25,000 daltons.

The activity of arabinogalactan-WR2721 was evaluated in the animal model as described above. Injection of 150 mg/kg of this substance was an effective blocker of the superparamagnetic iron-oxide colloid clearance, extending the half-life of the colloid to 86 minutes (Table 1).

Example 16: Arabinogalactan-WR2721 from phosphorylated arabinogalactan.

Arabinogalactan-phosphate (8 grams, example 9), 1.2 grams 1-ethyl -(3,4-dimethylaminopropyl)carbodiimide, and 1 gram of WR2721 are mixed together in 20 ml of water. The pH is adjusted to 7.5 with the addition of sodium hydroxide, and the mixture allowed to stand in the dark at room temperature for approximately 64 hours. The product, WR2721 linked to arabinogalactan through its primary amine esterified to the phosphate on arabinogalactan-phosphate, is purified by ultrafiltration (5 times 10 ml) using a YM3 (3000 daltons cutoff) and then freeze dried. The yield is 0.63 grams of white crystalline powder.

35 Characterization:

i. Molecular weight. Size exclusion chromatography (Amicon Cellufine GC200M) showed a single peak centered at

- 24 -

22 minutes, similar to that observed for arabinogalactan-phosphate starting material. No evidence was seen of low molecular weight impurities.

ii. Analysis of sulfhydryl content. The product phosphate 5 linked arabinogalactan-WR2721 is first hydrolyzed in 2M trifluoroacetic acid for 1 hour at 120°C. After neutralization, the sulfhydryl concentration is measured by a colorimetric test using 5,5' bisdithio 2-nitrobenzoic acid. The amount of WR2721 on arabinogalactan was 10 determined to be 0.063 milli-equivalents per gram of product.

iii. Enzyme catalyzed hydrolysis. Both alkaline phosphatase (Biozyme Code ALPI-12G) at pH 8.0 and acid phosphatase (EC3.1.3.2, from potato) at pH 4.8 were found to 15 rapidly hydrolyze the phosphothioate ester and thus unblock the thiol. The rate of hydrolysis by the acid phosphatase was 0.1 micro-equivalents phosphate/minute at 27°C, a rate which is close to that expected from the hydrolysis of p-nitrophenyl phosphate.

20 Example 17: Arabinogalactan-pepstatin. (2% amine by weight polysaccharide) through a N-hydroxy succinimide ester [Furuno, K., et.al. (1983) J. Biochem 93: 249]. Arabinogalactan with a primary amine is prepared 25 according to Example 2 (arabinogalactan-hydrazide) or example 5 or 7 (polylysine-arabinogalactan). Dissolve pepstatin A (250 mg) in 1 ml of dimethylformamide. Then add 50 mg 1-ethyl-3(3-dimethyl-aminopropyl)carbodiimide and 30 mg of N-hydroxy succinimide. After the reaction has proceeded at room temperature for 2 hours, add the mixture dropwise to 30 ml of 0.1 M sodium bicarbonate containing 100 mg of amino-arabinogalactan. Allow the resultant mixture to sit at room temperature for 2 h, then purify the product by ultrafiltration using a 10,000 dalton cutoff, and then by 35 cationic exchange chromatography.

- 25 -

Example 18: Carboxymethyl-arabinogalactan from reaction of bromoacetic acid with arabinogalactan

Five grams of arabinogalactan is dissolved in 50 ml of 4N sodium hydroxide. To this is added 10 grams of
5 bromoacetic acid, and the mixture heated at 80°C for three hours. The reaction is terminated by cooling to room temperature then adjusting the pH to between 7.5 and 9 using concentrated hydrochloric acid. The product is isolated and purified by G-25 column chromatography and ultrafiltration
10 using an Amicon YM3 membrane. The extent of derivatization, ascertained by running the reaction with ¹⁴C labeled bromoacetic acid and measuring the specific activity of the product by liquid scintillation counting, is about 5.2 milli-equivalents of carboxymethyl groups per gram of
15 product.

The activity of this arabinogalactan acetate was evaluated in the animal model as described above. A dose of 150 mg/kg was not an effective blocker of the superparamagnetic iron-oxide colloid, extending the half-
20 life of the colloid only to 7.3 minutes, compared to 33.2 minutes for underivatized arabinogalactan (Table 1).

Example 19: Carboxyethyl-arabinogalactan from reaction of 2-bromopropionic acid with arabinogalactan

Five grams of arabinogalactan is dissolved in 50 ml of
25 4N sodium NaOH. To this is added 11 grams of 2-bromopropionic acid, and the mixture heated at 80°C for three hours. The reaction is terminated by cooling to room temperature, then adjusting the pH to between 7.5 and 9 using concentrated hydrochloric acid. The product is
30 isolated and purified by G-25 column chromatography and ultrafiltration using an Amicon YM3 membrane. The extent of derivatization, determined by acid/base titration, is about 1.3 milliequivalents propionate per gram of product.

The activity of arabinogalactan propionate was
35 evaluated in the animal model as described above. Use of 150 mg/kg of this substance showed it ineffective blocker in superparamagnetic iron-oxide colloid clearance assay,

- 26 -

extending the half-life of the colloid to 40.8 minutes (Table 1).

Example 20: Arabinogalactan-WR2721 from thiophosphorylated arabinogalactan

- 5 Thiophosphorylation of arabinogalactan. Ten grams of anhydrous arabinogalactan is suspended in 50 ml of triethylphosphate. After the addition of 10.5 ml (75 millimole) of anhydrous triethyl amine, the suspension is cooled in an ice-water bath. To the cooled suspension is
- 10 added dropwise with stirring 2.55 ml (25 millimole) of thiophosphoryl chloride. Once the addition is complete, the reaction mixture is warmed to room temperature and stirred for 72 hours. After this time, the arabinogalactanyl thiophosphorodichloridate product is hydrolyzed by adding 50.
- 15 ml of deionized ice-water and stirring for two hours. The solvent, triethyl phosphate, is removed from the reaction mixture by extraction with 2 times with 25 ml portions of chloroform. The pH of the aqueous phase is adjusted to between 9 and 9.5 by the addition of 1 N sodium hydroxide.
- 20 The product is purified by ultra-filtration (50 ml to 10 ml, four cycles) using an Amicon YM3 (3000 dalton cutoff) ultrafiltration membrane. The final retentate is lyophilized to dryness.

- Synthesis of 2-(3-aminopropylamino) ethyl bromide, dihydrobromide. The synthesis of 2-(3-aminopropylamino) ethyl bromide, dihydrobromide is as described in Example 14.

- Reaction of polythiophosphorylated arabinogalactan with 2-(w-aminopropylamino) ethyl bromide to form S-2-(3 aminopropylamino) ethyl-thiophosphate-arabinocalactan. Five
- 30 mmole of polythiophosphorylated arabinogalactan, sodium salt, is dissolved in 10 ml of water. To the above solution is added 5.5 mmole of 2-(3-aminopropylamino) ethyl bromide dihydrobromide dissolved in 10 ml of water. The clear solution is stirred for four hours at room temperature. The
- 35 resulting turbid solution is added dropwise to rapidly stirred 0°C ethanol. The resulting precipitate is collected by filtration. The product is washed twice with 25 ml

- 27 -

portions of warm (40-50°C) ethanol and vacuum dried.

Thioalkylation is confirmed by a colorimetric analysis with ninhydrin.

- 28 -

What is claimed is:

1. A carrier for forming a complex with a therapeutic agent for delivery thereof to a cell receptor located on the surface of a target tissue comprising:
 - 5 arabinogalactan modified at a site by a functional residue to produce a derivative in a manner that preserves the useful affinity of the derivative for the cell receptor.
 2. A carrier according to claim 1, wherein the site of modification is a hydroxyl group on the arabinogalactan.
 - 10 3. A carrier according to claim 1, wherein the arabinogalactan is modified at a plurality of sites.
 4. A carrier according to claim 2, wherein the arabinogalactan is modified at a plurality of sites and the number of functional residues is no less than one equivalent
 - 15 per mole of arabinogalactan and no more than the number of hydroxyl groups on arabinogalactan per mole of arabinogalactan.
 5. A carrier according to claim 1, wherein the functional residue is selected from the group consisting of
 - 20 phosphoryl, sulfhydryl, amino, halo, acylimidazole and carboxyl groups.
 6. A carrier according to claim 2, wherein the functional residue is selected from the group consisting of phosphoryl, sulfhydryl, amino, halo, acylimidazole and
 - 25 carboxyl groups.
 7. A carrier according to claim 1, wherein the functional residue is a polymeric molecule.
 8. A carrier according to claim 2, wherein the functional residue is a polymeric molecule.
 - 30 9. A carrier according to claim 7, wherein the functional residue is a polymeric molecule selected from the group consisting of dextran, dextrin, albumin and poly-L-lysine.
 10. A carrier according to claim 8, wherein the
 - 35 functional residue is a polymeric molecule selected from the group consisting of dextran, dextrin, albumin and poly-L-lysine.

- 29 -

11. A complex for delivery of a therapeutic agent to a cell receptor located on the surface of a target tissue comprising:

arabinogalactan modified by a functional residue to
5 produce a derivative in a manner that preserves the useful
affinity of the derivative for the cell receptor; and
a therapeutic agent associated with the derivative so
as to form a complex.

12. A complex according to claim 11, wherein the
10 therapeutic agent is an antiviral agent.

13. A complex according to claim 12, wherein the
antiviral agent is selected from the group consisting of
acyclovir, ARA-AMP and ARA-A.

14. A complex according to claim 11, wherein the
15 therapeutic agent is a radioprotective agent.

15. A complex according to claim 14, wherein the
radioprotective agent is S-2-(3 aminopropylamino)ethyl
phosphoric acid.

16. A complex according to claim 11, wherein the
20 therapeutic agent is a chemoprotective agent.

17. A complex according to claim 16, wherein the
chemoprotective agent is S-2-(3 aminopropylamino) ethyl
phosphoric acid.

18. A complex according to claim 16, wherein the
25 therapeutic agent is a free radical scavenger.

19. A complex according to claim 18, wherein the free
radical scavenger is selected the group consisting of a
melanin, Trolox, cysteamine derivatives, cationic
aminothiols and vitamin E derivatives.

20. A complex according to claim 11, wherein the
30 therapeutic agent is a polypeptide.

21. A complex according to claim 20, wherein the
polypeptide is pepstatin.

22. A complex according to claim 20, wherein the
35 polypeptide is an enzyme.

23. A complex according to claim 22, wherein the
enzyme is superoxide dismutase.

- 30 -

24. A complex according to claim 11, wherein the therapeutic agent is selected from the group consisting of a polyclonal antibody, a monoclonal antibody and an antibody fragment.

5 25. A complex according to claim 11, wherein the therapeutic agent is a DNA molecule.

26. A complex according to claim 25, wherein the DNA molecule is an antisense molecule.

10 27. A complex according to claim 11, wherein the therapeutic agent is a steroid.

28. A method of delivering a therapeutic agent to a cell receptor comprising:

modifying arabinogalactan at a site by a functional residue to produce a derivative in a manner that preserves
15 the useful affinity of the derivative for the cell receptor; and

associating a therapeutic agent with the derivative so as to form a complex.

20 29. A method according to claim 28, wherein the site is a hydroxyl group on the arabinogalactan.

30. A method according to claim 25, wherein the arabinogalactan includes modifying arabinogalactan at a plurality of sites.

25 31. A method according to claim 28, wherein the step of modifying arabinogalactan includes modifying arabinogalactan at a plurality of sites wherein the number of functional residues is no less than one equivalent per mole of arabinogalactan and no more than the number of hydroxyl groups on arabinogalactan per mole of
30 arabinogalactan.

32. A method according to claim 28, wherein the step of modifying the functional residue includes selecting the functional residue from the group consisting of phosphoryl, sulfhydryl, amino, halo, acylimidazol and carboxyl groups.

35 33. A method according to claim 29, wherein the step of modifying the functional residue includes selecting the functional residue from the group consisting of phosphoryl,

- 31 -

sulfhydryl, amino, halo, acylimidazol and carboxyl groups.

34. A method according to claim 28, wherein the functional residue is a polymeric molecule.

35. A method according to claim 28, wherein the
5 therapeutic agent is a polypeptide.

36. A method according to claim 35, wherein the polypeptide is an enzyme.

37. A method according to claim 35, wherein the polypeptide is superoxide dismutase.

10 38. A method according to claim 35, wherein the polypeptide is pepstatin.

39. A method according to claim 35, wherein the polypeptide is selected from the group consisting of a monoclonal antibody, a polyclonal antibody and an antibody
15 fragment.

40. A method according to claim 28, wherein the therapeutic agent is a DNA molecule.

41. A method according to claim 40, wherein the DNA molecule is an antisense molecule.

20 42. A method according to claim 28, wherein the therapeutic agent is a steroid.

43. A method according to claim 28, wherein the therapeutic agent is selected from the group consisting of an antiviral agent, a radioprotective agent and a
25 chemoprotective agent.

44. A method according to claim 43, wherein the radioprotective agent is S-2-(3 aminopropylamino) ethyl-thiophosphoric acid.

45. A method according to claim 43, wherein the
30 chemoprotective agent is S-2-(3 aminopropylamino) ethyl-thiophosphoric acid.

46. A method according to claim 43, wherein the chemoprotective agent is a free radical scavenger.

47. A method according to claim 46, wherein the free
35 radical scavenger is selected from a group consisting of a melanin, Trolox, cysteamine derivatives, cationic aminothiols and vitamin E derivatives.

- 32 -

48. A method according to claim 43, wherein the antiviral agent is selected from the group consisting of acyclovir, ARA-AMP and ARA-A.

49. A method according to claim 28, further comprising:
administering an effective amount of the complex to an organism having the cell receptor.

50. A method according to claim 29, further comprising:
10 administering an effective amount of the complex to an organism having the cell receptor.

51. A method according to claim 30, further comprising:
administering an effective amount of the complex to an
15 organism having the cell receptor.

52. A method according to claim 31, further comprising:
administering an effective amount of the complex to an
organism having the cell receptor.

53. A method according to claim 32, further comprising:
administering an effective amount of the complex to an
organism having the cell receptor.

54. A method according to claim 34, further comprising:
25 administering an effective amount of the complex to an organism having the cell receptor.

55. A method according to claim 35, further comprising:
30 administering an effective amount of the complex to an organism having the cell receptor.

56. A method according to claim 40, further comprising:
administering an effective amount of the complex to an
35 organism having the cell receptor.

57. A method according to claim 42, further comprising:

- 33 -

administering an effective amount of the complex to an organism having the cell receptor.

58. A method according to claim 43, further comprising:

5 administering an effective amount of the complex to an organism having the cell receptor.

59. A method according to claim 46, further comprising:

administering an effective amount of the complex to an
10 organism having the cell receptor.

60. A process for making a carrier that is suitable for forming a complex with a therapeutic agent for delivery thereof to a cell receptor, comprising:

providing arabinogalactan;

15 treating the arabinogalactan with an agent suitable for modifying the aldehyde content thereof to produce a derivative that preserves the useful affinity of the derivative with the cell receptor.

61. A process according to claim 60, wherein the agent
20 is suitable for increasing the aldehyde content of arabinogalactan.

62. A process according to claim 61, wherein the agent is galactose oxidase.

63. A process according to claim 62, wherein the step
25 of treating arabinogalactan includes the step of oxidizing arabinogalactan by galactose oxidase so as to contain at least one additional aldehyde and less than about 1.2 milliequivalents of aldehydes per gram of polysaccharide.

64. A process according to claim 63, wherein the agent
30 is suitable for decreasing the aldehyde content of arabinogalactan.

65. A process according to claim 60, wherein the agent is a reducing agent containing borohydride.

66. A process according to claim 65, wherein the
35 borohydride is selected from the group consisting of sodium borohydride and sodium cyanoborohydride.

67. A process according to claim 60, wherein the step

- 34 -

of treating arabinogalactan includes hydrolyzing arabinogalactan by an endo-beta galactosidase enzyme.

68. A process according to claim 60, wherein the step of treating arabinogalactan includes reacting the
5 arabinogalactan with anhydrides selected from the group consisting of succinate, glutarate and diethylenepentaacetic acid.

69. A process according to claim 60, wherein the step of treating arabinogalactan includes the step of reacting
10 the arabinogalactan with a primary amine to produce a Schiff's base and treating the product with a reducing agent.

INTERNATIONAL SEARCH REPORT

PCT/US 92/05091

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K47/48; C08B37/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61K ; C08B	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	WO,A,9 001 295 (ADVANCED MAGNETICS) 22 February 1990 see page 5, line 22 - page 6, line 15; claims 1,15,40,41,51 see page 22, line 1 - line 14; example 6.10.1	1-69
Y	EP,A,0 331 821 (KUREHA KAGAKU KOGYO KABUSHIKI KAISHA) 13 September 1989 see claims	1-69
Y	DE,A,3 200 766 (TOYO JOZO CO.) 16 September 1982 cited in the application see page 20 - page 22; claims 1,5,6,11	1-69
	-/--	
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
17 MARCH 1993	28. 34. 93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	BERTE M.J.	

III. D. CLEMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	
Y	<p>DATABASE WPIL Week 8550, Derwent Publications Ltd., London, GB; AN 85-314078 & JP,A,60 219 202 (DAICEL CHEM. IND. KK.) 1 November 1990 cited in the application see abstract</p> <p>-----</p>	1-69

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9205091
SA 61829

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 17/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9001295	22-02-90	EP-A- 0381742	16-08-90
		JP-T- 4501218	05-03-92
		US-A- 5141739	25-08-92
EP-A-0331821	13-09-89	JP-A- 1199593	10-08-89
DE-A-3200766	16-09-82	JP-C- 1480442	10-02-89
		JP-A- 57118509	23-07-82
		JP-B- 63030290	17-06-88
		JP-B- 4068289	02-11-92
		JP-A- 57146722	10-09-82
		JP-A- 57146723	10-09-82
		JP-C- 1603432	04-04-91
		JP-B- 2029052	27-06-90
		JP-A- 58085813	23-05-83
		CA-A- 1184492	26-03-85
		DE-T- 3250023	29-03-90
		FR-A,B 2497669	16-07-82
		GB-A,B 2092002	11-08-82
		SE-B- 460638	06-11-89
		SE-A- 8200103	15-07-82
		US-A- 4900730	13-02-90
		JP-A- 57135033	20-08-82
		US-A- 4609640	02-09-86

EPO FORM 60079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82